Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aztreonam lysine: Additional Phase III data

Additional data from the double-blind Phase III AIR-CF1 trial in 164 patients showed that 75

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE